Lupin stock reaches highest point in eight years, with strong earnings outlook.

From Business Standard: 2024-07-04 13:01:48

Lupin Pharma’s stock hits an eight-year high, doubling in value in the last year with a consensus valuation of 33 times its FY25 earnings estimates. Analysts at Kotak Institutional Equities upgrade the stock to ‘add’ from ‘sell’ with a fair value of Rs 1,805, citing strong US portfolio potential. Lupin has a strong $200 million plus revenue from the US market, expected to be sustained with new product launches in FY25. Antique Stock Broking bullish on Lupin, predicts US generic revenue to exceed $1 billion by FY27.



Read more at Business Standard: Lupin stock hits eight-year high at Rs 1,749 on healthy earnings outlook | Stock Market Today